/ /

  • linkedin
  • Increase Font
  • Sharebar

    Looking to long-range keratoprosthesis outcomes

    Chicago—Findings from a single-surgeon consecutive series including 97 eyes with up to 12 years of follow-up provide realistic insights for corneal surgeons about long-term outcomes after implantation of the Boston keratoprosthesis type 1 (“Boston KPro”; Massachusetts Eye and Ear Infirmary).

    The information—which included analyses of visual acuity results, device retention rates, and complications associated with the permanent keratoprosthesis—was presented by Anthony J. Aldave, MD, at Cornea 2016.

    Dr. Aldave noted that long-term results of the Boston KPro was the subject of a retrospective study published about 2 years ago [Ophthalmology. 2014;12:2159-2164].

    “I was fortunate to be part of that group and consider it a very important publication,” said Dr. Aldave, professor of ophthalmology, The Stein Eye Institute, University of California, Los Angeles.

    “However, the data are from a multicenter cohort and reflect many different surgeons with different indications for surgery and different postoperative management regimens,” he said. “I wanted to look at the long-term outcomes of the Boston Kpro in my experience as a single surgeon.”

    His series included 93 patients and encompassed 120 implantation procedures performed between May 2004 and May 2011. The average follow-up was just under 5 years.

    The most common indication for the Boston Kpro procedure was failed corneal transplant (57%) followed by Stevens Johnson syndrome (SJS; 11%) and chemical injury (10%).

    “In almost every KPro series, failed corneal transplant is the most common indication, and we know that SJS and chemical injury are associated with a more guarded long-term prognosis,” Dr. Aldave said.

    Significant visual improvement

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results